Skip to main content

Bristol-Myers Squibb

(BMY)

and

Novartis

(NVS)

agreed to co-develop and co-promote Zelmac, Novartis' new investigational drug treatment for women with certain symptoms associated with irritable bowel syndrome.

The treatment has been filed with regulatory authorities worldwide. The agreement between the companies would exclude Japan.

The companies will also collaborate in developing two Bristol-Myers Squibb immune-modulating compounds for transplantation and autoimmune uses.